KY-1044
Based on 1 Customer Validation
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.51%
- CAS No.: 2489390-15-8
- 분자량:146.5 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ICOS/CD278
In Vitro
KY-1044 (Alomfilimab; SAR 445256; 0-100ng/mL; 4 hours) causes human natural killer (NK) cells expressing hICOS (5:1 effector:target cell ratio) to induce potent ADCC-mediated killing (EC50=5.6 pmol/L)[1].
KY-1044 significantly induces the luciferase signal (EC50 of 0.15 nmol/L). A similar EC50 is obtained against mouse ICOS (0.53 nmol/L), rat ICOS (0.48 nmol/L), or cynomolgus monkey ICOS (0.22 nmol/L)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
In syngeneic mouse tumor models, KY-1044 depletes ICOShigh Treg and increases the intratumoral TEff:Treg ratio, resulting in increased secretion of IFNγ and TNFα by TEff cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8- to 10-week-old wild-type female Balb/C or C57BL/6J mice with A20 cells[1]
-
Dosage:200 μg (10 mg/kg)
-
Administration:IP; twice a week for 3 weeks starting from 6 days following tumor cell implantation
-
Result:Triggered an antitumor response, with more than 90% of the mice being free from measurable disease at the end of the study (day 42).
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized ICOS Protein, Human can bind Alomfilimab. The EC50 for this effect is 11.35 ng/mL. -
Chemical Information
-
CAS No. 2489390-15-8
-
Appearance Liquid
-
분자량 146.5 kDa
-
Color Colorless to light yellow
-
SMILES
[KY-1044]
-
Synonyms
Alomfilimab; SAR 445256
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)